- Published on
Curi Bio Raises $10M in Series B Funding
- Author
-
-
- Name
- Posts
- Posts
-
Curi Bio, a Seattle, WA-based company delivering human-relevant functional data for drug discovery and development, raised $10M in Series B funding.
The round was led by DreamCIS.
The company intends to use the funds to accelerate the development of new platforms for cardiac, skeletal muscle, metabolic, smooth muscle, and neuromuscular diseases and expand its commercial reach across the globe.
Led by CEO and PhD Nicholas A. Geisse and CBO Elliot Fisher, Curi Bio generates novel workflows and delivers functional human data to inform biopharmaceutical R&D decision making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and advanced automated data analysis, it enables functional and analytical assessments for drug safety, efficacy, and potency.
The three-pronged platform strategy integrates:
source[FinSMEs]
The round was led by DreamCIS.
The company intends to use the funds to accelerate the development of new platforms for cardiac, skeletal muscle, metabolic, smooth muscle, and neuromuscular diseases and expand its commercial reach across the globe.
Led by CEO and PhD Nicholas A. Geisse and CBO Elliot Fisher, Curi Bio generates novel workflows and delivers functional human data to inform biopharmaceutical R&D decision making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and advanced automated data analysis, it enables functional and analytical assessments for drug safety, efficacy, and potency.
The three-pronged platform strategy integrates:
- human cells:
- advanced systems;
- advanced data analysis.
source[FinSMEs]
0 Comments